CONTACT

Yenkel GRINBERG-BLEYER

Team leader, CRCN Inserm

Cheney B, 4th floor

VOISIN Allison
LALLE Guilhem
STEPHAN Pierre

M2 student

Voir les objectifs et projets Voir les publications
Collaborations
Ulf KLEIN, Leeds University, UK
Stephane DALLE, Hôpitaux Lyon-Sud et CRCL, France
Gilles MARODON, CIMI, Paris, France
Christophe CAUX, CRCL, Lyon, France
Caroline WILSON, Newcastle University, UK
Benoit SALOMON, CIMI, Paris, France

Grants
Programme Atip-Avenir
Labex DEVweCAN
Fondation ARC
Fondation BMS
Fondation ARSEP

OBJECTIVES

Cancer progression is often indexed to the quality of the anti-tumor immune response. Conversely, these immune responses can be deleterious in the settings of autoimmune diseases. In this context, understanding the molecular mechanisms orchestrating the function of immune cells in their target tissues, is of major interest for the development of new therapies for cancer and autoimmunity. The team “Molecular Regulation of Cancer Immunity” is particularly interested in the role of the NF-kB family of transcription factors in T-cell biology. Our recent work has demonstrated specific and divergent functions of the different NF-kB subunits in the function of regulatory T cells, which are potent inhibitors of immunity. Our goal now is to decipher the possible roles of NF-kB in the function of effector T cells (Teff), which have dual functions: protective in cancer and pathogenic in autoimmune diseases. Our work may not only reveal new mechanisms of regulation of the immune system, but also highlight new therapeutic targets for the treatment of cancer or autoimmunity.

PROJETS

The research of the team is articulated around 3 major projects:

-The characterization of NF-kB subunits in the basal Teff biology.

-The study of NF-kB functions in cancer progression and response to immunotherapies.

-The study of the impact of NF-kB in the pathogenic functions of Teff in autoimmune diseases.

This research is based on a common methodology in 3 axes:

-The use of unique pre-clinical mouse models.

-The use of patient samples and the ablation of NF-kB in vitro in human cells

-High-throughput sequencing (RNA-seq, CHIP-Seq, ATAC-Seq) to understand NF-kB functions at the whole genome level.


 

 

 

 

PUBLICATIONS

Grinberg-Bleyer Y, Caron R, Seeley JJ, De Silva NS, Schindler CW, Hayden MS, Klein U, Ghosh S. “The Alternative NF-κB Pathway in Regulatory T Cell Homeostasis and Suppressive Function.J Immunol. 2018 Apr 1;200(7):2362-2371.

Grinberg-Bleyer Y., Oh H., Desrichard A., Bhatt D.M., Caron R., Chan T.A., Schmid R., Hayden M.S., Klein U., and Ghosh S. “NF-kB c-Rel is crucial for the regulatory T cell immune checkpoint in cancer.” Cell, 2017 Sep 7;170(6):1096-1108

Oh H.*, Grinberg-Bleyer Y.*, Liao W., Maloney D., Wang P., Wu Z., Wang J., Bhatt D.M., Heise N., Schmid R., Hayden M.S., Klein U., Rabadan R. and Ghosh S. (* Equal contribution) “An NF-kB-dependent, lineage specific transcriptional program regulates Treg identity and function.” Immunity, 2017 Sep 19;47(3):450-465

Grinberg-Bleyer Y, Ghosh S. “A novel link between inflammation and cancer.” Cancer Cell, 2016 Dec 12; 30(6):829. Review.

 

Grinberg-Bleyer Y, Dainichi T, Oh H, Heise N, Klein U, Schmid RM, Hayden MS, Ghosh S. “Cutting edge: NF-κB p65 and c-Rel control epidermal development and immune homeostasis in the skin.  J Immunol. 2015 Mar 15;194(6):2472

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :